Erasca (NASDAQ:ERAS - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.1301) per share for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.
Erasca (NASDAQ:ERAS - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). On average, analysts expect Erasca to post ($0.49) EPS for the current fiscal year and ($0.65) EPS for the next fiscal year.
Erasca Price Performance
NASDAQ ERAS opened at $14.64 on Wednesday. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of -15.41 and a beta of 0.68. The company's fifty day moving average is $15.35 and its two-hundred day moving average is $15.04. Erasca has a 52-week low of $2.11 and a 52-week high of $24.28.
Analysts Set New Price Targets
A number of brokerages have recently commented on ERAS. Guggenheim upped their price objective on shares of Erasca from $20.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Jefferies Financial Group reissued a "buy" rating on shares of Erasca in a research report on Tuesday, July 14th. Morgan Stanley upped their price target on Erasca from $12.00 to $21.00 and gave the company an "equal weight" rating in a report on Monday, July 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Erasca in a report on Tuesday, September 8th. Finally, Bank of America raised their price objective on Erasca from $18.00 to $20.00 and gave the stock a "neutral" rating in a research report on Friday, August 14th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $22.09.
View Our Latest Analysis on ERAS
About Erasca
(
Get Free Report)
Erasca, Inc NASDAQ: ERAS is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with RAS/MAPK pathway-driven cancers. The company's research and development programs are designed to target molecular alterations that contribute to tumor growth and treatment resistance, including mutations involving the RAS family of proteins and related signaling pathways.
Erasca's pipeline has included small-molecule oncology candidates such as naporafenib, a pan-RAF inhibitor being studied in cancers with aberrant RAS/MAPK signaling, as well as additional investigational therapies intended to address difficult-to-treat oncogenic drivers.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.